GlaxoSmithKline PLC ADR (GSK)vsIntel Corporation (INTC)
GSK
GlaxoSmithKline PLC ADR
$54.71
+3.32%
HEALTHCARE · Cap: $104.12B
INTC
Intel Corporation
$47.18
+7.08%
TECHNOLOGY · Cap: $220.09B
Smart Verdict
WallStSmart Research — data-driven comparison
Intel Corporation generates 62% more annual revenue ($52.85B vs $32.67B). GSK leads profitability with a 17.5% profit margin vs -0.5%. INTC appears more attractively valued with a PEG of 0.50. GSK earns a higher WallStSmart Score of 70/100 (B).
GSK
Strong Buy70
out of 100
Grade: B
INTC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+66.0%
Fair Value
$172.22
Current Price
$54.71
$117.51 discount
Intrinsic value data unavailable for INTC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 43 in profit
Earnings expanding 54.7% YoY
Large-cap with strong market position
Attractively priced relative to earnings
Generating 1.5B in free cash flow
Mega-cap, among the largest globally
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Trading at 10.1x book value
Elevated debt levels
Distress zone — elevated risk
Distress zone — elevated risk
ROE of 0.0% — below average capital efficiency
Revenue declined 4.1%
Earnings declined 71.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : GSK
The strongest argument for GSK centers on PEG Ratio, Return on Equity, EPS Growth. Profitability is solid with margins at 17.5% and operating margin at 18.9%. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bull Case : INTC
The strongest argument for INTC centers on Market Cap, PEG Ratio, Price/Book. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bear Case : GSK
The primary concerns for GSK are Price/Book, Debt/Equity, Altman Z-Score.
Bear Case : INTC
The primary concerns for INTC are Altman Z-Score, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
GSK profiles as a mature stock while INTC is a turnaround play — different risk/reward profiles.
INTC carries more volatility with a beta of 1.38 — expect wider price swings.
GSK is growing revenue faster at 6.2% — sustainability is the question.
GSK generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
GSK scores higher overall (70/100 vs 42/100), backed by strong 17.5% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GlaxoSmithKline PLC ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
Intel Corporation
TECHNOLOGY · SEMICONDUCTORS · USA
Intel Corporation is an American multinational corporation and technology company headquartered in Santa Clara, California, in Silicon Valley. It is the world's largest semiconductor chip manufacturer by revenue, and is the developer of the x86 series of microprocessors, the processors found in most personal computers (PCs).
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?